Gholam Motamedi

Gholam Motamedi practices at Medstar Medical Group II in Arlington, Virginia.

Gholam Motamedi's NPI, 1801884192, was assigned on October 11, 2005. Gholam Motamedi graduated from Tehran University of Medical Sciences School of Medicine in 1987. Gholam Motamedi holds District of Columbia license 32662.

Gholam Motamedi's primary practice is Medstar Medical Group II, at 2000 15th N St, Arlington, VA 22201 in Arlington County. The practice phone is (443) 444-5606.

Gholam Motamedi's primary practice is Medstar Medical Group II in Arlington, Virginia. Gholam Motamedi is also affiliated with MedStar Georgetown University Hospital. The medical group on file is MedStar Medical Group. Dmand AI also links Gholam Motamedi to 1 more hospital and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Gholam Motamedi practices, 2 sites in all. Vendor and product names are available with a free account.

Neurology is Gholam Motamedi's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Gholam Motamedi is board certified in clinical neurophysiology by the American Board of Psychiatry and Neurology. Dmand AI has Gholam Motamedi's licenses on file in 4 states: District of Columbia, Utah, Virginia and Maryland.

Dmand AI lists dementia, epilepsy, mobility impairment, seizures and sleep apnea among the conditions Gholam Motamedi treats.

CMS data shows 384 Medicare services from Gholam Motamedi across 5 procedure codes in 2024, for 297 Medicare patients. Medicare paid $49,042 for them.

CMS counts 297 Medicare patients who saw Gholam Motamedi in 2024. The largest group is 65 to 74, with 104 patients. 75% of them have high blood pressure, and 70% have high cholesterol. 39% are also on Medicaid. Their average risk score is 1.88, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Gholam Motamedi's median patient age at 47, with 54% women.

In 2024, Gholam Motamedi wrote 1,012 Medicare Part D claims for 127 patients. 79% of them were for generic drugs. CMS names the drug for 925 of them, across 26 drugs with 11 or more claims each, at $321,497 in total drug cost. In 2023, CMS named 786 claims across 23 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Gholam Motamedi for performance year 2024, reported as part of a group. Gholam Motamedi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Gholam Motamedi as offering telehealth.

Dmand AI links 54 papers to Gholam Motamedi, published from 2006 to 2025. 2019 was the busiest year, with 6. The most frequent topics are Electroencephalography, Epilepsy and Anticonvulsants. Gholam Motamedi has published most often in Epilepsy Behav. Gholam Motamedi's most frequent co-authors are William D. Gaillard, Kimford Jay Meador, MD and William Lynn Bell, MD.

Dmand AI links Gholam Motamedi to 1 clinical trial. Conditions studied include Drug Resistant Epilepsy and Seizures.

CMS Open Payments shows 135 general payments to Gholam Motamedi from 10 drug and device companies from 2016 to 2024. Speaker and faculty fees make up the largest share, 72% of the total. Supernus Pharmaceuticals, Inc. paid the most, $44,526.

Dmand AI lists 2 awards for Gholam Motamedi, most recently CMS Stage 1 2012 in 2012.

Gholam Motamedi graduated from Tehran University of Medical Sciences School of Medicine in 1987.

Gholam Motamedi is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.